In the Phase 2b cohort, 70% of patients remained injection-free for 52 weeks, while the Phase 1/2a cohort saw an 83% reduction in annualized injections. How significant is this reduction in treatment burden for wet AMD patients, especially compared to the current standard of care?

The study observed durable treatment effects across both the severe and broad wet AMD populations. What does this durability mean for the long-term management of wet AMD, and how could it impact the frequency of follow-up visits required for patients?

4D-150 demonstrated sustained control of central subfield thickness (CST) and stable or improved best corrected visual acuity (BCVA). How important is this anatomic and functional stability in maintaining long-term vision outcomes for wet AMD patients?

With 4D-150 showing a safety profile similar to approved anti-VEGF agents, including a low rate of intraocular inflammation, what are the key takeaways for clinicians in terms of the safety and tolerability of this gene therapy option?

The Phase 2b data indicated that 87% of recently diagnosed patients were injection-free for 52 weeks. Could this suggest that initiating treatment with 4D-150 early in the disease course might offer particular advantages in disease management?

The upcoming 4FRONT-1 Phase 3 trial will compare a single dose of 4D-150 to on-label aflibercept. What are the advantages of this trial design, and how does it reflect the expectations of both regulatory agencies and clinicians regarding the potential for 4D-150?

Given the expected initiation of the 4FRONT-1 trial in Q1 2025 and the alignment with both FDA and EMA under RMAT and PRIME designations, respectively, what are the key factors that could influence the clinical, regulatory, and commercial success of 4D-150 in wet AMD?

With wet AMD currently requiring frequent, lifelong intravitreal injections, how could the introduction of 4D-150 change the overall treatment landscape, and what potential benefits does it offer in terms of patient compliance and real-world outcomes compared to current therapies?